Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).
⁃ All patients:
• Adults (\>18 years)
• Presenting with cutaneous psoriasis
• Patients have signed an informed consent
• Beneficiary of the health insurance, except for the AME Only for patients of Group 1
• Patients require systemic treatment for psoriasis
• Patients are naïve to biological therapies
⁃ Only for patients of Group 2:
• Patients requiring treatment with anti-IL-23 biologics (guselkumab, risankizumab, tildrakizumab) upon referent physician's decision.
• Patients are naïve to biological therapies or have received only one biologic, with a wash-out period of at least 4 months
⁃ Non inclusion Criteria:
⁃ For all :
• Patient is minor
• Patient is pregnant or breastfeeding
• Patient is immunocompromised
• Patient is under legal protection, curatorship, guardianship
• Patient refuses consent
• Patient is unable to comply with study requirements for geographic, social or psychiatric reason.
• Beneficiary of the AME Only for patients of Group 1
• Patient has received biologics Only for patients of Group 2
• Patient has a contraindication to the chosen biotherapy
• Patient has received biologics within the last 4 months
• Patient has been treated with 2 or more biologics
• Patient has already received an anti-IL-23 biologic